News & Deep Analysis
JNJ

Johnson & Johnson Q3 2025: Revenue up 6.8%

Published: October 14, 2025
JOHNSON & JOHNSON

Direct News

  • Q3 revenue up 6.8% year-over-year
  • Q3 sales: $22,471 million
  • Q3 net earnings: $5,152 million — nearly double the year-ago quarter
  • Company has raised full-year sales guidance
  • Balance sheet (Sep 28, 2025): total assets $192,816 million; shareholders' equity $79,277 million

Historical Context

These Q3 2025 results sit within a multi-quarter performance pattern documented in the company's filings. Reported net earnings include Q1 net earnings of $10,999 million and H1 cumulative net earnings of $16,536 million; adding Q3 net earnings of $5,152 million yields 9-month net earnings of $21,688 million. Johnson & Johnson, founded in 1886 and headquartered in New Brunswick, New Jersey, employs approximately 138,200 people worldwide and continues to pursue growth through R&D in oncology, immunology, neuroscience and device innovation across cardiovascular, orthopaedics, surgery and vision care. The company has previously disclosed the strategic intention to separate its Orthopaedics Business, an initiative that presents both potential value-creation and execution risk as it proceeds.

Quarterly highlights and drivers

Johnson & Johnson reported Q3 2025 sales of $22,471 million, an increase of 6.8% on a year-over-year basis. Q3 net earnings were $5,152 million, a result described as nearly double the comparable quarter a year earlier. On a year-to-date basis, combining the reported figures for Q1, H1 and Q3 produces 9-month net earnings of $21,688 million (H1 cumulative $16,536 million plus Q3 $5,152 million). The company said it has raised its full-year sales guidance following the quarter, signaling confidence in revenue momentum across its businesses.

Segment emphasis: Innovative Medicine and MedTech

Johnson & Johnson continues to operate through two core segments: Innovative Medicine and MedTech. Innovative Medicine includes oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular/metabolism, with key products cited in filings such as CARVYKTI, DARZALEX/DARZALEX FASPRO, ERLEADA, IMBRUVICA, RYBREVANT, STELARA, TREMFYA, CAPLYTA and CONCERTA. MedTech comprises cardiovascular/electrophysiology and heart recovery (including Abiomed), circulatory restoration technologies (such as Shockwave), neurovascular, orthopaedics, surgery and vision care (ACUVUE and TECNIS intraocular lenses). The Q3 results and the raised sales guidance reflect contributions across both segments, with operational execution and protected pharmaceutical franchises highlighted in the company profile.

Balance sheet and financial scale

At quarter end (Sep 28, 2025) the company's balance sheet showed total assets of $192,816 million and shareholders' equity of $79,277 million. The scale of reported quarterly sales ($22,471 million) and multi-billion-dollar net earnings underscore Johnson & Johnson's financial heft, while the company cites continued investment in R&D and product development within Innovative Medicine and MedTech as central to sustaining growth.

Competitive position and moat considerations

Filings emphasize patents and IP protection as the primary source of competitive advantage for the Innovative Medicine portfolio. High-value patent protection underpins franchises such as CAR-T therapies and DARZALEX, but the company notes vulnerability to patent challenges and eventual generic or biosimilar entry. MedTech relies on enabling technologies (for example, Abiomed and Shockwave) and procedural innovation, but faces commoditization risk in some device categories. Overall, the structural moat is concentrated in patent-protected pharmaceuticals; operational execution drives MedTech performance.

Risks to watch after Q3

The company reiterates a broad set of risks in its filings that remain relevant following Q3: product liability and litigation exposure; government investigations and potential civil or criminal penalties; regulatory actions including recalls or withdrawals; pricing and reimbursement pressures from payors and provider consolidation; supply chain or manufacturing disruptions; cybersecurity threats; geopolitical and macroeconomic volatility; and clinical or regulatory setbacks in development programs. The planned separation of the Orthopaedics Business is also flagged as an execution risk.

Investor FAQ

The most effective approach is to maintain a factual perspective. Keep a close watch on further developments at JOHNSON & JOHNSON as they unfold. Use primary source data to validate your investment thesis rather than relying on delayed secondary reports.

You can set up an automated tracker on Portrak. Our system monitors official SEC filings in real-time, delivering the most critical insights to your phone or inbox seconds after publication—frequently before the information reaches major financial news platforms.

We believe quality intelligence should be accessible. Our business model is supported by professional investors with large, complex portfolios who utilize Portrak Pro. These users pay to automate the monitoring of extensive watchlists, saving hundreds of hours in research time, which allows us to keep the standard service free for individual investors tracking their core positions.

Setting up your automated intelligence pipeline is a simple 3-step process:

1

Create Your Free Account

Sign up or log in to access your personal dashboard.

2

Select Your Focus

Use the search bar to find companies like JOHNSON & JOHNSON. Choose between monitoring specific events or receiving general market-moving intelligence. Our AI automatically determines what’s critical based on real-time market data and the company’s current profile.

3

Receive Real-Time Intelligence

Once activated, all official filings are analyzed instantly. Insights are delivered directly to your email or as a push notification if you use the Portrak mobile app.

Also available as a mobile app for iOS & Android—search for "Portrak"

More Strategic Insights

JNJ
Oct 14, 2025

J&J Reports FDA Approvals, AI Launch — JNJ News

Read Analysis
JNJ
Oct 14, 2025

JNJ Board & DePuy Synthes Leadership Update

Read Analysis
JNJ
Oct 14, 2025

J&J Restructures MedTech Operations

Read Analysis
JNJ
Oct 14, 2025

JNJ: Namal Nawana Named President of DePuy Synthes

Read Analysis